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Metastatic prostate cancer continues to be the second leading cause of cancer death in American men with an estimated 28,660 deaths in 2008.
Recently, monocyte chemoattractant protein-1 (MCP-1, CCL2) has been identified as an important factor in the regulation of prostate
metastasis. CCL2, shown to attract macrophages to the tumor site, has a direct promotional effect on tumor cell proliferation, migration, and
survival. Previous studies have shown that anti-CCL2 antibodies given in combination with docetaxel were able to induce tumor regression in
a pre-clinical prostate cancer model. A limitation for evaluating new treatments for metastatic prostate cancer to bone is the inability of
imaging to objectively assess response to treatment. Diffusion-weighted MRI (DW-MRI) assesses response to anticancer therapies by
quantifying the random (i.e., Brownian) motion of water molecules within the tumor mass, thus identifying cells undergoing apoptosis. We
sought to measure the treatment response of prostate cancer in an osseous site to docetaxel, an anti-CCL2 agent, and combination treatments
using DW-MRI. Measurements of tumor apparent diffusion coefficient (ADC) values were accomplished over time during a 14-day treatment
period and compared to response as measured by bioluminescence imaging and survival studies. The diffusion data provided early predictive
evidence of the most effective therapy, with survival data results correlating with the DW-MRI findings. DW-MRI is under active investigation
in the pre-clinical and clinical settings to provide a sensitive and quantifiable means for early assessment of cancer treatment outcome. J. Cell.
Biochem. 107: 58–64, 2009.  2009 Wiley-Liss, Inc.KEY WORDS: PROSTATE CANCER; CHEMOTHERAPY; MACROPHAGESI t is projected by the American Cancer Society that in 2008,186,320 men will develop prostate cancer within the United
States [Jemal et al., 2008]. Prostate cancer is the second most
common form of cancer in American men with an estimated 28,660
deaths in 2008, which makes it the second most common cause of
cancer death. Although primary hormone deprivation therapy is
successful in most men, many patients develop hormone refractory
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Recently, several reports have indicated that chemokines have an
important role in the regulation of tumorigenesis, contributing to
cancer progression of several adenocarcinomas including breast
and prostate cancer [Youngs et al., 1997; Vanderkerken et al., 2002].
CCL2 is a member of the chemokine family that has been shown to58
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attract monocytes and macrophages to the tumor site inducing
an inflammatory response which promotes tumor growth. This
macrophage invasion is shown to be the predominant mechanism by
which CCL2 stimulates tumor growth [Loberg et al., 2007a]. In
addition, CCL2 has been shown to have a direct promotional effect
on tumor cell proliferation, migration, and survival [Loberg et al.,
2007a]. Previous studies have shown that mouse (C1142) and human
(CNTO888) CCL2 antibodies (anti-CCL2) given in combination with
docetaxel were able to induce tumor regression in a pre-clinical
prostate cancer model [Loberg et al., 2007b].
A limitation in the drug development process for evaluating new
treatments for metastatic prostate cancer is the inability of imaging
to objectively assess response to treatment. Current imaging
strategies to evaluate early treatment response in metastatic prostate
cancer residing within bone in the clinic are unavailable [Hamaoka
et al., 2004], and the Response Evaluation Criteria in Solid Tumors
(RECIST) system explicitly mentions bone tumors to be non-
measurable [Therasse et al., 2000]. This emphasizes the importance
of developing and implementing new imaging methods for
measurement of treatment response for this disease. Diffusion-
weighted MRI (DW-MRI) holds great promise for assessing response
to anticancer therapies. DW-MRI can be used to quantify the random
(i.e., Brownian) motion of water molecules within intact living tissue
[Moffat et al., 2004]. This imaging approach is very appealing as a
biomarker of early treatment response as the diffusion of water
molecules within a tumor are hindered by cellular membranes.
Successful treatment, which results in the loss of tumor cells,
reduces the barriers which impede the mobility of the water
molecules. DW-MRI provides an imaging method for quantification
of water diffusion values and is reported as an apparent diffusion
coefficient (ADC). ADC values will increase in tumor regions
experiencing a loss of cellular density. This principle was first
demonstrated using a chemotherapy-treated rodent glioma model
[Ross et al., 1994] and was subsequently validated in a variety of
pre-clinical studies assessing the response to anticancer agents
including cytotoxic and cytostatic therapies, radiation therapy, and
gene therapy [Zhao et al., 1996; Chenevert et al., 1997, 2000, 2002;
Hakumaki et al., 1998; Poptani et al., 1998; Ross et al., 1998, 2003;
Galons et al., 1999; Chinnaiyan et al., 2000; Stegman et al., 2000;
Jennings et al., 2002; Hall et al., 2004; Hamstra et al., 2004; Moffat
et al., 2004; Theilmann et al., 2004; Jordan et al., 2005; Schepkin
et al., 2006; Lee et al., 2006a,b, 2007a,b,c; Kim et al., 2008].
Treatment-induced changes in tumor ADC values were found to
occur early and prior to tumor volumetric changes providing the
rationale for using this imaging biomarker as an early predictive
marker of treatment response [Chenevert et al., 2000]. Thus,
DW-MRI is under active investigation in the pre-clinical and clinical
settings to provide a sensitive and quantifiable means for early
assessment of cancer treatment outcome.
We have recently reported that DW-MRI can provide an early
indication of treatment response in tumors located within the
skeletal system using a mouse model of metastatic prostate cancer to
the bone [Lee et al., 2007c]. Furthermore, we have also demonstrated
the feasibility of using DW-MRI in a patient with metastatic
hormone sensitive prostate cancer which demonstrated a correla-
tion between diffusion changes and a decrease in PSA levelsJOURNAL OF CELLULAR BIOCHEMISTRYconsistent with a positive treatment response [Lee et al., 2007d]. The
current study is aimed at measuring the treatment response of
prostate cancer in an osseous site to docetaxel, an anti-CCL2 agent,
and combination treatments using DW-MRI to evaluate if this




The PC3 human androgen independent cancer cell line is derived
from a human prostate cancer metastasis to bone. The PC3 cells were
transfected with a luciferase-expressing plazarus retroviral con-
struct as previously described [Kalikin et al., 2003]. Luciferase
produces light in the presence of Luciferin and oxygen, making the
transfected cells distinguishable from the host rodent cells using a
bioluminescence imaging system (BLI). Wild-type PC3 cells were
cultured in RPMI 1640 supplemented with 10% fetal bovine
serum, while transfected PC3luc were maintained in selection media
supplemented with 200 mg/ml G418.
AGENTS
Anti-CCL2 antibodies, C1142 and CNTO888 were supplied by
Centocor, Inc., CNTO888 is a human IgG1k antibody that neutralizes
human CCL2. C1142 is a rat/mouse chimeric antibody that
neutralizes mouse CCL2. Anti-CCL2 therapy consisted of simulta-
neous administration of both antibodies. Docetaxel (Taxotere) was
obtained from the University of Michigan Hospital Pharmacy.
MICE
Male severe combined immunodeficient mice (SCID, T-cell and
B-cell deficient) were purchased from Charles River (Wilmington,
MA). The mice were housed in pathogen-free rooms at the University
of Michigan internationally accredited facilities in microisolator
cages. Mice were anesthetized using a 2% isofluorane/air mixture
and 2 105 PC3luc cells were introduced by intracardiac injection in
the left ventricle. PC3luc cells spread throughout the body and
typically produced several sites of bone metastases. Two separate
groups of animals were prepared for these studies. Study I consisted
of a total of 48 animals which were used to evaluate the effects of the
experimental treatments on tumor control. Study II consisted of a
total of 40 animals from which 23 were selected to undergo MRI and
BLI. Study I animals began treatments 2 weeks after cell inoculation
whereas Study II animals began treatments once tumors became of
sufficient size to study by MRI (6–12 ml).
BLI
To identify mice with bone metastases in the tibia, BLI was
performed 4 weeks after PC3luc injection using a highly sensitive
CCD camera (IVIS 200; Caliper Life Sciences, Alameda, CA). All
animals from Study II entered the bioluminescence study (n¼ 40),
and based on the bioluminescence images a subset was selected
(n¼ 23) to enter the MRI study. To perform BLI, mice were
anesthetized with a 2% isofluorane/air mixture and 150 mg/kg
D-luciferin was administered by intraperitoneal injection. Ten to
12 min after IP injection, bioluminescence images were acquiredDW-MRI IN METASTATIC PROSTATE CANCER 59
Fig. 1. Measurement of total body tumor burden over time for Study I
animals bearing PC3luc tumor cells as quantified by BLI photon counts. Animals
representing the four treatment groups are shown. Mean SEM is shown for
each group; tumor burden is shown while 8 of 12 mice remained on study for
each group. Mice were treated with docetaxel at weeks 2, 3, and 4 at 40 mg/kg;
anti-CCL2 antibodies were administered at 2 mg/kg twice a week starting at
week 2 and continuing for the duration of the study. All treatment groups
showed significantly reduced tumor burden as compared to the PBS group from
weeks 4 to 6 (P< 0.001); both docetaxel treatment groups showed signifi-
cantly reduced tumor burden as compared to the anti-CCL2 antibody group
from weeks 4–8 (P 0.013); the docetaxel/anti-CCL2 group showed signifi-
cantly reduced tumor burden as compared to docetaxel alone from weeks 9 to
12 (P 0.021).using a FOV of 25 cm, a binning factor of 2, f/1 lens setting and an
exposure time of 15 s. The mice were kept under anesthesia in the
bioluminescence detector using a nose cone system to deliver the
isofluorane/air mixture and the animal stage was heated to 378C to
maintain the core body temperature of the animal.
Previous efforts had found that bioluminescence photon counts
were directly proportional to the number of tumor cells; allowing for
quantification of the number of tumor cells in a lesion [Lee et al.,
2007c; Loberg et al., 2007b]. A baseline bioluminescence scan was
acquired before initiation of treatment. After initiation of treatment
bioluminescence scans were acquired each week until the animals
were euthanized. Regions of interest (ROI) were manually drawn
around the animals using the Living ImageTM software 2.5 provided
with the BLI system. The photon count (photons/s) within an ROI was
used as a quantitative measure of the total tumor burden in the
animals. The photon counts collected throughout the study were
normalized to the photon counts measured at baseline. This
approach provided for the measurement of treatment response and
disease progression over time.
TREATMENT
Study I. The effects of docetaxel, anti-CCL2 and a combination of
the two agents were evaluated and compared to untreated (PBS
treated) animals using bioluminescence imaging to follow the
growth of PC3luc cells in mice (n¼ 12 mice per group). Animals
began treatment two weeks following cell inoculation. Animals
treated with docetaxel were dosed with 40 mg/kg/week for 3 weeks
while anti-CCL2 was administered at 10 mg/kg twice weekly for the
duration of the study. BLI was conducted weekly on each of the
animals. Quantification of photon counts was accomplished at each
time point, and an average value was determined for each group of
mice over time to allow for quantification of temporal changes in
‘‘tumor burden’’ for the different treatment groups. Animals were
euthanized when they became moribund.
Study II. Twenty-three animals were selected to enter the MRI
study which were divided into four groups; an untreated group
(n¼ 4), a docetaxel treated group (n¼ 10, 40 mg/kg/week for 3
weeks), an anti-CCL2 treated group (n¼ 4, 10 mg/kg twice weekly
until animals became moribund) and a combination group treated
with docetaxel and anti-CCL2 (n¼ 5, docetaxel 40 mg/kg/week for
3 weeks and anti-CCL2 10 mg/kg twice weekly until animals became
moribund).
MRI
During MRI examinations, animals were anesthetized with 1.5%
isofluorane/air mixture and their body temperatures maintained at
378C using an Air-Therm heater (World Precision Instruments,
Sarasota, FL). MRI images were acquired on a Varian 9.4 T animal
MR-scanner (120 mm horizontal bore; Varian, Palo Alto, CA) using a
20 mm volume SAW coil (M2M imaging, Cleveland, OH). The
animal’s leg was suspended in the center of the coil by attaching to
the toe a ligature which was fastened to the coil frame. T2-weighted
anatomical images were acquired using a fast spin-echo sequence
with the following parameters: FOV¼ 20 20 mm; TR/TE¼ 4000/
52 ms; echo train length¼ 8; echo spacing¼ 13 ms; 24 interleaved
slices (contiguous); thickness¼ 0.5 mm; matrix¼ 256 128;60 DW-MRI IN METASTATIC PROSTATE CANCER2 signal averages. DW images were acquired using a spin-echo
sequence, with a navigator echo and gradient waveforms sensitive
to isotropic diffusion [Moffat et al., 2004], with the following
parameters: FOV¼ 20 20 mm; TR/TE¼ 4000/37 ms; 18 inter-
leaved slices (contiguous); thickness¼ 0.5 mm; gap¼ 0.1 mm;
matrix¼ 128 128 (readout phase); averages¼ 1; b values¼
120 s/mm2 and 1200 s/mm2. Placement of the slice package for
the DW images was based on lesion position as determined from the
anatomical images.
STATISTICAL ANALYSIS
Repeated measures analyses of variance were conducted on tumor
burden assuming first-order autocorrelation covariance structures.
Natural splines were used to flexibly model the curvature of trends
in the time profiles. Comparisons between the groups were
performed at each of the time points using a Student’s t-test.
Logarithmic transformations were performed prior to analyses to
better satisfy the underlying statistical modeling assumptions of
equal variance and sampling from populations with normal
distributions. Time to disease-related death was evaluated using
life table methods. The log-rank test was used for comparisons
among treatment groups. P-values less than 0.05 were considered
significant.
RESULTS
OVERALL TREATMENT RESPONSE AND SURVIVAL
(STUDY I ANIMALS)
To evaluate the long-term impact of docetaxel and anti-CCL2
antibody therapy, an experiment was performed to measure the
effects of treatment on prostate cancer growth in mice (Fig. 1).JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 3. Bioluminescence imaging data pre- and post-treatment initiation for
Study II treated animals. Normalized photons are presented for control (black
square), anti-CCL2 (blue inverted triangle), docetaxel (red triangle), and the
combination of docetaxel and anti-CCL2 treated animals (purple inverted
triangle) at days 6, 8 and 14 post treatment initiation. Data displayed as
mean SEM.Animals were sacrificed per protocol when the animals became
moribund or tumor burden by photon count reached maximum
tolerated count [Loberg et al., 2007b]. Significant inhibition in
tumor growth rates were observed by BLI for all test groups, with the
combination of docetaxel and anti-CCL2 treatment having the
greatest effect, followed by docetaxel and anti-CCL2, which had
slightly reduced growth rates over control animals. The reduction in
tumor growth rates in the treated animals was reflected in animal
survival for the different treatment groups (Fig. 2). Overall survival
was found to be greatest with the combination docetaxel/anti-CCL2
antibody group followed by docetaxel alone and anti-CCL2. Median
survival for control animals was 6 weeks, anti-CCL2 antibodies:
11 weeks (P¼ 0.006 vs. PBS control); docetaxel alone: 15 weeks
(P¼ 0.021 vs. anti-CCL2 antibodies); and combination therapy:
22 weeks (P< 0.001 vs. any other group). These results demonstrate
that combination therapy of docetaxel/anti-CCL2 antibodies was
more effective than either monotherapy to prolong tumor growth
inhibition and extend survival.
EVALUATION OF IMAGING BIOMARKERS OF TREATMENT
RESPONSE (STUDY II ANIMALS)
A separate group of animals (Study II) was prepared to evaluate the
ability of DW-MRI to detect differential responses to the therapies
based upon differences in the magnitude of changes in tumor water
diffusion values. Initial BLI was done for all animals (n¼ 40) at
4 weeks post-intracardiac PC3luc injection to identify those animals
with intratibial lesions. A subset of animals (n¼ 23) that showed
metastatic disease in the tibia was selected to enter the MRI study
and treatment was initiated following baseline MRI scans. Animals
from the control group and the anti-CCL2 group demonstrated a
continuous increase in the bioluminescence signal intensity over the
first 14 days of the experiment as shown in Figure 3. Animals from
the docetaxel-treated group and the group of animals treated with
the combination of docetaxel and anti-CCL2 demonstrated a stable
to decreasing bioluminescence signal over the 14-day period of the
experiment. Since the photon counts quantified from each lesion are
proportional to the number of luciferase positive PC3 cells present, it
would be anticipated that the volume of the tumors would also
reflect the relative changes (or lack thereof) in the BLI signal levels.Fig. 2. Animal survival plot for PC3luc inoculated animals for each of the
treatment groups in Study I. Mice were treated with docetaxel at weeks 2, 3,
and 4 at 40 mg/kg; anti-CCL2 antibodies were administered at 2 mg/kg twice a
week starting at week 2 and continuing for the duration of the study.
JOURNAL OF CELLULAR BIOCHEMISTRYIn this regard, tumor volumes for individual animals were obtained
over time using anatomical T2-weighted MRI. The control and anti-
CCL2 treated groups showed a continuous increase in tumor volume
up to an 8.0-fold increase and 6.5-fold increase on day 14,
respectively. Although not significant, the anti-CCL2 treated group
had a slightly diminished growth rate relative to the untreated
group. The docetaxel and combination docetaxel/anti-CCL2 treated
groups demonstrated stable tumor volumes and slight regression,
respectively based upon the MRI-determined volumetric measure-
ments (Fig. 4). When comparing the docetaxel treated group or the
combination group to the control group, a significant reduction in
tumor volumes were found on days 6 and 10 (P< 0.05).
DW-MRI was also used to evaluate the treatments in the Study II
animals since this imaging modality is sensitive for the detection of
cell death rather than cell cycle arrest. Measurements of tumor ADC
values were accomplished over time during the 14-day treatmentFig. 4. Normalized tumor volumes from tibial PC3 tumors obtained over time
using MRI (Study II). Values shown are from baseline (day 0) and at days 3, 6,
10, and 14 post-treatment initiation. Normalized tumor volume presented
correspond to control (black square), anti-CCL2 (blue inverted triangle),
docetaxel (red triangle), and the combination of docetaxel and anti-CCL2
treated animals (purple inverted triangle). Data displayed as mean SEM.
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Fig. 5. Representative ADC maps of PC3 tumor shown as color overlays on
T2-weighted images (Study II). ADC maps were acquired pre-treatment (day 0)
(left column) and 14 days post-treatment initiation (right column). Image
pairs are from four different animals representing control (A,B), anti-CCL2
(C,D), docetaxel (E,F) and combination therapy with docetaxel and anti-
CCL2 therapy (G,H). Color scale represents tumor ADC values 0 to 200
105 mm2/s.
Fig. 6. PC3 tumor ADC values 14 days following therapy normalized to
baseline (Study II). Data displayed as mean SEM.period. Shown in Figure 5 are quantitative ADC values displayed as a
color overlay on the anatomical T2-weighted MR images from
representative animals from each of the four treatment groups at
baseline (Fig. 5A,C,E,G) and at 14 days post-treatment initiation
(Fig. 5B,D,F,H). The color overlays reveal the quantitative ADC
values on a voxel-by-voxel basis for the tumors at baseline (day 0)
and at 14 days post-treatment initiation. Baseline tumor diffusion
values reveal relatively low diffusion of between 90 and 125
105 mm2/s (yellow to green color). Small pockets of higher
diffusion values are observable pre-treatment which can likely be
attributable to focal areas of spontaneous necrosis within the tumor
mass. Following 14 days of therapy, it is apparent that the docetaxel
(Fig. 5F) and combination of docetaxel and anti-CCL2 (Fig. 5H)
treated animals had the largest shift in ADC values as evidenced by
the large amount of yellow to red color-encoded voxels within the
tumor mass. In addition to ADC, these images provide for observing
the relative changes in tumor volumes for each animal. Quantifica-
tion of tumor diffusion values was accomplished at each time point
from ROI’s drawn to circumscribe the tumor volume. Control (PBS)62 DW-MRI IN METASTATIC PROSTATE CANCERand anti-CCL2 treatment groups generated stable mean ADC values
throughout the 14-day treatment period (data not shown). As shown
in Figure 6, combination of docetaxel and anti-CCL2 treatment
groups had the most significant increase in ADC values (P< 0.05) as
compared to all other groups. Significant differences were not
observed between the other groups. The anti-CCL2 group, due to
attrition of animals and negligible changes in ADC, was pooled over
days 10 and 14.
DISCUSSION
In this current study, DW-MRI was used to evaluate differential
effects of docetaxel, anti-CCL2 and a combination of docetaxel and
anti-CCL2 treatments on PC3 tumor growth in a mouse bone tumor
model. It was previously shown by Loberg et al. [2007b] using BLI
that anti-CCL2 treatment was able to slow tumor growth rate as well
as delay tumor recurrence after docetaxel treatment was stopped.
Moreover, a previous study had also found that docetaxel was able
to induce tumor regression and that DW-MRI was able to detect a
tumor response before significant tumor volume changes were
observed [Lee et al., 2007c]. Based upon these previous studies,
this series of experiments was undertaken to evaluate the ability of
DW-MRI to detect differences in treatment-associated changes in
tumor cellularity using water diffusion as a surrogate marker in
single and combination agents of docetaxel and anti-CCL2 during
the early phase of treatment.
MRI-determined tumor volume data (Fig. 4) revealed that there
was an attenuation of tumor growth rate between the control and
anti-CCL2 treated groups (growth rate for control is 0.52 vs. 0.45 for
anti-CCL2 treated with the growth rate defined as the power in the
exponential fit through the volume data). The docetaxel and
docetaxelþ anti-CCL2 treatment groups both inhibited tumor
growth similarly over the course of the 14-day imaging study.
Tumor volume measurements over the 2-week period were
incapable of delineating any synergy between anti-CCL2 and
docetaxel from docetaxel alone. Moreover, BLI was also not able to
detect differences in tumor cell kill values between the docetaxel
and combination groups as both groups displayed similar stableJOURNAL OF CELLULAR BIOCHEMISTRY
photon counts over time (Fig. 3). Furthermore, the control and anti-
CCL2 groups produced increasing BLI photon counts over time with
no differences between them. As the error bars were fairly large,
additional numbers of animals may possibly allow for a more
definitive conclusion.
The use of imaging to provide feedback related to the efficacy of a
treatment has been a subject of great interest. In this study, we also
utilized DW-MRI in an effort to see if this quantitative imaging
method could detect differences in efficacy between the treatment
groups. Diffusion of water molecules within the tumor mass is
affected by the number of tumor cells present per unit volume,
as cell membranes limit the movement of water molecules thus
restricting their diffusion or Brownian motion. During treatments
which result in a net loss of cellular membranes, diffusion values
increase in those regions. Therefore, by quantification of the
changes in tumor water diffusion values using DW-MRI during
treatment, it should in principle be possible to differentiate between
treatments which have different therapeutic effectiveness.
In this study, diffusion measurements of PC3 tumors over time
revealed increases in water ADC values in response to both
docetaxel and combined docetaxel with anti-CCL2 treatments.
However, as shown in Figure 6, the combination therapy group
revealed a larger increase in diffusion values at day 14 as compared
with the docetaxel alone. The diffusion data provided early evidence
that the more effective therapy would be anticipated to be the
combination group as the combination therapy was found to have
the largest overall increased change in diffusion values. Animal
survival data (Fig. 2) revealed that the combination therapy, in fact,
provided enhanced survival over docetaxel alone, thus corroborat-
ing the DW-MRI findings. The anti-CCL2 treatment may inhibit the
attraction of macrophages to the tumor site. As previously noted,
these macrophages promote a chronic inflammation which can
result in stimulation of tumor growth. However, this feature was not
found as there appeared to be a modest decrease in tumor growth
rates and improved survival with anti-CCL2 treatment.
In conclusion, the magnitude of the changes in tumor diffusion
values as quantified by DW-MRI were determined to provide an
early readout of changes in tumor cellularity during the treatments
administered in this study, and were reflective of overall impact on
tumor growth and animal survival. Measurement of tumor ADC
values and comparing these values to BLI measurements provide
complementary information. However, DW-MRI can be translated
in the clinical setting and as such, it is possible to use this imaging
biomarker in Phase I, II, or III clinical trials.ACKNOWLEDGMENTS
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